DeepMed Research

Huazhong University Of Science And Technology Press Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Application of n-3 Fatty to Patient of Jaundice

Completed

Conditions: Obstructive Jaundice
Surgical Procedure, Unspecified

Interventions: Drug: trail cohort
Drug: control cohort

First Posted Date: 2017-12-19

Last Posted Date: 2017-12-19

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 106

Registration Number: NCT03376945

Locations: 🇨🇳
Hepatic Surgery Center of Tongji Hospital, Wuhan, Hubei, China

TMTP1-ICG Mapping in Colposcopy-directed Biopsy

Phase 1

Conditions: Cervical Intraepithelial Neoplasia

Interventions: Drug: TMTP1
Drug: ICG

First Posted Date: 2017-10-25

Last Posted Date: 2021-06-30

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 40

Registration Number: NCT03321461

Locations: 🇨🇳
Tongji Hospital, Tongji Medical Colledge, HUST, Wuhan, Hubei, China

TMVP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer

Phase 1

Conditions: Cervical Cancer

Interventions: Drug: TMVP1-ICG
Drug: ICG

First Posted Date: 2017-10-25

Last Posted Date: 2017-10-25

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 40

Registration Number: NCT03320772

Locations: 🇨🇳
Tongji Hospital, Tongji Medical Colledge, HUST, Wuhan, Hubei, China

TMTP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer

Phase 1

Conditions: Cervical Cancer

Interventions: Drug: TMTP1-ICG
Drug: ICG

First Posted Date: 2017-10-25

Last Posted Date: 2017-10-27

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 40

Registration Number: NCT03321448

Locations: 🇨🇳
Tongji Hospital, Tongji Medical Colledge, HUST, Wuhan, Hubei, China

The Effect of Vaccinium Myrtillus L. Extract Intake on Human Metabolism

Not Applicable

Conditions: Healthy

Interventions: Dietary Supplement: Vaccinium Myrtillus L. extract
Dietary Supplement: Placebo

First Posted Date: 2017-10-20

Last Posted Date: 2018-04-10

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 80

Registration Number: NCT03316612

Locations: 🇨🇳
Huazhong University of Science and Technology, Wuhan, Hubei, China

Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC

Phase 3

Conditions: Hepatocellular Carcinoma

Interventions: Drug: ADV-Tk
Procedure: LT

First Posted Date: 2017-10-18

Last Posted Date: 2019-02-04

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 180

Registration Number: NCT03313596

Locations: 🇨🇳
The Third XiangYa Hospital of Central South University, Changsha, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, China
🇨🇳
The Third Affiliated Hospital,Sun Yat-sen University, Guangzhou, China

and more 8 locations

Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients

Phase 3

Completed

Conditions: Uterine Cervical Neoplasm
Cervical Cancer
Uterine Cervical Cancer

Interventions: Drug: NACT
Procedure: RT+PLND
Drug: Adjuvant chemotherapy

First Posted Date: 2017-10-12

Last Posted Date: 2024-10-31

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 774

Registration Number: NCT03308591

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Comparison Between Costoclavicular and Paracoracoid Ultrasound-guided Infraclavicular Block for Forearm Surgery

Not Applicable

Conditions: Brachial Plexus Block

Interventions: Procedure: paracoracoid infraclavicular block
Procedure: costoclavicular infraclavicular block
Device: Ultrasound
Drug: Ropivacaine

First Posted Date: 2017-09-12

Last Posted Date: 2017-09-12

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 50

Registration Number: NCT03279679

Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer

Conditions: Uterine Cervical Neoplasms
Cervical Cancer
Uterine Cervical Cancer

First Posted Date: 2017-07-25

Last Posted Date: 2020-06-16

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 240

Registration Number: NCT03229187

Locations: 🇨🇳
Tongji Hospital, Wuhan, Hubei, China

Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions

Phase 1

Conditions: Human Papillomavirus-Related Malignant Neoplasm

Interventions: Biological: T512

First Posted Date: 2017-07-21

Last Posted Date: 2022-01-14

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 40

Registration Number: NCT03226470

Locations: 🇨🇳
Tongji Hospital, Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy